Clinical Trial Update: Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant [Phase 3]

View source ↗

Summary

Pfizer is conducting a Phase 3 trial comparing elranatamab to lenalidomide in patients with newly diagnosed multiple myeloma after autologous stem cell transpla…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Elranatamab (elranatamab)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Pfizer | Conditions: Multiple Myeloma | Phase 3 | Status: ACTIVE_NOT_RECRUITING